Meet the Team:
Frank Avellanet President, CEO & Co-founder
Eduardo de Marchena Medical Advisor & Co-founder
Keith Webster Scientific Advisor & Co-founder
Joaquin Jimenez Vascular Injury / Thrombosis Advisor & Co-Founder
Fotios Andreopoulos Biomaterials Advisor & Co-Founder
Roberto Vazquez-Padron Vascular Biology Advisor & Co-Founder
Frank J. Avellanet
President, CEO & Co-founder
Frank Avellanet is a results oriented entrepreneur/executive with 30 years of broad management experience and effective leadership in the medical device industry. He co-founded Miami Cardiovascular Innovations Corporation in 2006. Mr. Avellanet excels as a technical leader and motivator of cross-functional teams focusing on moving products from concept to commercialization. As an expert in product development, specifically cardiovascular products, he holds 27 patents and has participated in the successful development, manufacturing, FDA approval and commercialization of dozens of life-saving medical products.
Prior to founding Miami Cardiovascular Innovations, his broad background in product development led to a number of executive level-assignments in the areas of business development, R&D, product development, program management, and manufacturing operations at such companies as Cordis Corp., a Johnson & Johnson Company, US Surgical Corp., a Covidien Company, Medcomp Technologies, Beckman-Coulter, and Stereotaxis, Inc.
He began his career designing, developing and testing pacemakers and pacing leads at Cordis, as well as developing and manufacturing surgical instruments and new manufacturing processes. He also gained extensive entrepreneurial experience by founding and serving as president & CEO of Scilogy Corporation, a company focused on the development and commercialization of cardiovascular and gastroenterology products. He also co-founded Physicians Data Services, Bodylog Inc, Cathguide Corporation and A-Square Development. Mr. Avellanet holds a BS in Mechanical Engineering from Farleigh Dickinson University, and conducted graduate studies in engineering at Tufts University. He is certified in Lean Six Sigma.
Eduardo de Marchena, M.D., F.A.C.C., F.A.C.P.
Medical Advisor & Co-founder
Associate Dean for International Medicine
Chairman of University of Miami Medical Group
Professor of Medicine and Surgery
Director of Interventional Cardiology
Medical Director University of Miami Cardiovascular Center
University of Miami, Leonard M. Miller School of Medicine
Dr. Eduardo de Marchena, a nationally recognized cardiologist, is a professor of medicine and surgery at the University of Miami’s School of Medicine. In addition, Dr. de Marchena serves as the Director of Interventional Cardiology as well as the Director of the School’s Cardiovascular Center. He is also the Chairman of the University of Miami Medical Group.
Dr. de Marchena has more than 25 years of professional experience in his medical career. He received his medical degree from the University of Miami’s School of Medicine and completed his residency at Jackson Memorial Hospital. Following his residency Dr. de Marchena served as Chief Medical Resident in internal medicine, and subsequently received a fellowship in the Division of Cardiology.
Dr. de Marchena holds three board certifications of the National Boards of Medical Examiners; Boards of Internal Medicine, Boards of Cardiovascular Disease and Boards of Interventional Cardiology.
During his tenure at the University of Miami Miller School of Medicine, Dr. de Marchena started the key programs of Heart transplantation and Interventional Cardiology. He has also served as the Chief of the Division of Cardiology.
In addition to his clinical and academic work, Dr. de Marchena’s research in interventional cardiology, coronary artery disease, atherosclerosis and congestive heart failure has been widely published. He has over 200 publications and abstracts in journals including; New England Journal of Medicine, Circulation, Journal of the American College of Cardiology, American Heart Journal, Progress in Cardiology, and Journal of Vascular Surgery. He is the co-editor of the “Secrets in Interventional Cardiology” textbook
Dr. de Marchena has also been widely recognized for his accomplishments. He received the Best Cardiology Attending award, presented by the University of Miami Cardiology Fellows, four times between 1988 and 2000, and also received the Martin H. Stein Memorial Award for Superior Performance as a cardiology fellow. In addition, during his residency, Dr. de Marchena was named Best Resident of the Year. He has also been recognized by the Cuban Medical Society, AOA and the Iron Arrow society. He has been recognized multiple times by the Best Doctors in America.
Dr. de Marchena holds several patents and patent applications in percutaneous cardiovascular devices, has delivered countless medical education presentations and has directed numerous symposiums in diverse areas of Cardiology throughout the United States and Latin America.
Keith Webster, Ph.D.
Scientific Advisor & Co-founder
Professor of Molecular and Cellular Pharmacology; Director of the Vascular Biology Institute; Walter G. Ross Chair of Vascular Biology
B. A. in Biology , University of York, England
Ph.D. in Biochemistry, University of York, England
Senior Research Associate, Dept. of Genetics, Stanford University, California.
Assistant Professor, Dept of Biochemistry, USC, Los Angeles, Calif. (1988)
Senior Scientist, SRI International (1993)
Program Director, Molecular Cardiology Laboratory, SRI International, (1996)
Associate Professor, University of Miami , Miami, FL. (1998)
President & CEO of Integene Inc. (Intelligent Gene and Cell Therapy)
Molecular mechanisms of hypoxia/ischemia-regulated gene expression.
Molecular pathology of vascular disease.
Control of cell death in ischemic heart disease/protective strategies.
Gene therapy with "Intelligent Gene" delivery techniques.
Joaquin Jimenez, MD
Vascular Injury / Thrombosis Advisor & Co-Founder
Dr. Joaquin J. Jimenez is well known for his research on leukemia, hematopoietic stem cells, including endothelial progenitors, and mucocutaneous complications of chemotherapy. More recently, he has has expanded his research repertoire to include novel concepts such as endothelial microparticles and their relation to thrombosis and vascular biology.
He has more than 150 articles scientific papers and abstracts in prestigious peer-reviewed scientific journals such as Science, Blood and Cancer Research as well as book chapters. Dr. Jimenez trained in Internal Medicine at Jackson Memorial Hospital/University of Miami School of Medicine. Subsequently, he completed a fellowship in Research Hematology under Dr. Adel A. Yunis, one of world pioneers in stem cell hematopiesis and growth factors. Dr. Joaquin J. Jimenez has been a faculty at the University of Miami Miller School of Medicine for the past 19 years.
Fotios Andreopoulos, Ph.D.
Biomaterials Advisor & Co-Founder
University of Pittsburgh, PA; Ph.D. in Chemical and Petroleum Engineering; August 1999
University of Pittsburgh, PA; Masters in Bioengineering; August 1996
University of Texas at Austin, TX ;Bachelor's in Chemical and Petroleum Engineering; December 1993.
Georgia Institute of Technology, GA; Certificate in Tissue Engineering; April 1997.
Biomaterials (BME 335), Advanced Biomaterials BME (BME 535), Principles of Cellular and Tissue Engineering (BME 565), Artificial Internal Organs (BME 617)
Biomaterials, drug delivery, tissue engineering, clinical utilization of mechanical circulatory assist devices.
Vascular Injury / Thrombosis Advisor & Co-Founder
Dr. Vazquez-Padron, is an Assistant Professor in the Cardiothoracic Transplantation Research Laboratory and is a member of the Vascular
Biology Institute at The Miller School of Medicine, University of Miami. He received his PhD from the University of Havana, Havana,
Cuba. Dr. Vazquez-Padron has published more than 50 scientific papers and abstracts in molecular and vascular biology. His research work is
focused in the science of coronary vascular disease and in-stent restenosis to improve the understanding, management, and outcomes of
coronary interventions. His work also includes molecular pathways that regulate the genetic susceptibility to restenosis with the long-term
aim of designing better coronary therapies.
Last webpage update (August 29, 2008):
To be a leader in the development of cardiovascular diagnostic and therapeutic devices with a special focus on the next generation of products which merge clinical medicine, vascular biology and biomedical engineering.